Citations

Citations to this article as recorded by  

• Aggregation-Induced Emission Luminogens: A New Possibility for Efficient Visualization of RNA in Plants
  Zheng-Chao Yang, Li-Xiang Zhao, Yu-Qi Sang, Xin Huang, Xuan-Chen Lin, Zhi-Ming Yu
  Plants.2024; 13(5): 743.     CrossRef
• Oxidative Stress and Dopaminergic Metabolism: A Major PD Pathogenic Mechanism and Basis of Potential Antioxidant Therapies
  Aamir Rasool, Robina Manzoor, Kaleem Ullah, Ramsha Afzal, Asad Ul-Haq, Hadia Imran, Imdad Kaleem, Tanveer Akhtar, Anum Farrukh, Sahir Hameed, Shahid Bashir
  CNS & Neurological Disorders - Drug Targets.2024; 23(7): 852.     CrossRef
• Effectiveness of Flavonoid-Rich Diet in Alleviating Symptoms of Neurodegenerative Diseases
  Aneta Szulc, Karolina Wiśniewska, Magdalena Żabińska, Lidia Gaffke, Maria Szota, Zuzanna Olendzka, Grzegorz Węgrzyn, Karolina Pierzynowska
  Foods.2024; 13(12): 1931.     CrossRef
• Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut
  Jacqui T. Nimmo, Harry Smith, Chang Yi Wang, Jessica L. Teeling, James A. R. Nicoll, Ajay Verma, Jean-Cosme Dodart, Zhi Liu, Feng Lin, Roxana O. Carare
  Acta Neuropathologica.2022; 143(1): 55.     CrossRef
• Autophagy-Related Pathways in Vesicular Unconventional Protein Secretion
  Shin Hye Noh, Ye Jin Kim, Min Goo Lee
  Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
• Targeting Macroautophagy as a Therapeutic Opportunity to Treat Parkinson’s Disease
  Irene Sanchez-Mirasierra, Saurav Ghimire, Sergio Hernandez-Diaz, Sandra-Fausia Soukup
  Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
• A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson’s disease: application to preladenant
  Rachel Rose, Emma Mitchell, Piet Van Der Graaf, Daisuke Takaichi, Jun Hosogi, Hugo Geerts
  Journal of Pharmacokinetics and Pharmacodynamics.2022; 49(6): 593.     CrossRef
• Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases
  Falguni Baidya, Mariya Bohra, Aishika Datta, Deepaneeta Sarmah, Birva Shah, Priya Jagtap, Swapnil Raut, Ankan Sarkar, Upasna Singh, Kiran Kalia, Anupom Borah, Xin Wang, Kunjan R. Dave, Dileep R. Yavagal, Pallab Bhattacharya
  Immunology.2021; 162(2): 160.     CrossRef
• Electrogastrography for diagnosis of early-stage Parkinson's disease
  Nobuyuki Araki, Yoshitaka Yamanaka, Anupama Poudel, Yoshikatsu Fujinuma, Akira Katagiri, Satoshi Kuwabara, Masato Asahina
  Parkinsonism & Related Disorders.2021; 86: 61.     CrossRef
• Natural Alkaloid Compounds as Inhibitors for Alpha-Synuclein Seeded Fibril Formation and Toxicity
  Simona S. Ghanem, Hend S. Fayed, Qi Zhu, Jia-Hong Lu, Nishant N. Vaikath, Janarthanan Ponraj, Said Mansour, Omar M. A. El-Agnaf
  Molecules.2021; 26(12): 3736.     CrossRef
• Tat-p27 Ameliorates Neuronal Damage Reducing α-Synuclein and Inflammatory Responses in Motor Neurons After Spinal Cord Ischemia
  Woosuk Kim, Hyun Jung Kwon, Hyo Young Jung, Kyu Ri Hahn, Seung Myung Moon, Yeo Sung Yoon, In Koo Hwang, Soo Young Choi, Dae Won Kim
  Neurochemical Research.2021; 46(12): 3123.     CrossRef
• Immunotherapies for Parkinson’s Disease: Progression of Clinical Development
  Jet Shee Teng, Yin Yin Ooi, Soi Moi Chye, Anna Pick Kiong Ling, Rhun Yian Koh
  CNS & Neurological Disorders - Drug Targets.2021; 20(9): 802.     CrossRef
• Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection
  Sheila K. Pirooznia, Liana S. Rosenthal, Valina L. Dawson, Ted M. Dawson, Eric Barker
  Pharmacological Reviews.2021; 73(4): 1204.     CrossRef
• Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here?
  Khalil Mallah, Christine Couch, Davis M. Borucki, Amer Toutonji, Mohammed Alshareef, Stephen Tomlinson
  Frontiers in Immunology.2020;[Epub]     CrossRef
• Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance
  Miguel Lemos, Serena Venezia, Violetta Refolo, Antonio Heras-Garvin, Sabine Schmidhuber, Armin Giese, Andrei Leonov, Sergey Ryazanov, Christian Griesinger, Gergana Galabova, Guenther Staffler, Gregor Karl Wenning, Nadia Stefanova
  Translational Neurodegeneration.2020;[Epub]     CrossRef
• Insights Into Peptide Inhibition of Alpha-Synuclein Aggregation
  James H. Torpey, Richard M. Meade, Ravina Mistry, Jody M. Mason, Jillian Madine
  Frontiers in Neuroscience.2020;[Epub]     CrossRef
• Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
  Jacqui T. Nimmo, Ajay Verma, Jean-Cosme Dodart, Chang Yi Wang, Jimmy Savistchenko, Ronald Melki, Roxana O. Carare, James A. R. Nicoll
  Alzheimer's Research & Therapy.2020;[Epub]     CrossRef
• Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives
  Khosro Jamebozorgi, Eskandar Taghizadeh, Daryoush Rostami, Hosein Pormasoumi, George E. Barreto, Seyed Mohammad Gheibi Hayat, Amirhossein Sahebkar
  Molecular Neurobiology.2019; 56(7): 4799.     CrossRef
• The Associations between Immunological Reactivity to the Haptenation of Unconjugated Bisphenol A to Albumin and Protein Disulfide Isomerase with Alpha-Synuclein Antibodies
  Datis Kharrazian, Martha Herbert, Aristo Vojdani
  Toxics.2019; 7(2): 26.     CrossRef
• Effects of single and combined immunotherapy approach targeting amyloid β protein and α‐synuclein in a dementia with Lewy bodies–like model
  Markus Mandler, Edward Rockenstein, Cassia Overk, Michael Mante, Jazmin Florio, Anthony Adame, Changyoun Kim, Radmila Santic, Achim Schneeberger, Frank Mattner, Sabine Schmidhuber, Gergana Galabova, Brian Spencer, Eliezer Masliah, Robert A. Rissman
  Alzheimer's & Dementia.2019; 15(9): 1133.     CrossRef
• Translational therapies for multiple system atrophy: Bottlenecks and future directions
  Nadia Stefanova
  Autonomic Neuroscience.2018; 211: 7.     CrossRef
• Integrin CD11b mediates α-synuclein-induced activation of NADPH oxidase through a Rho-dependent pathway
  Liyan Hou, Xiuqi Bao, Caixia Zang, Hanyu Yang, Fuqiang Sun, Yuning Che, Xuefei Wu, Shao Li, Dan Zhang, Qingshan Wang
  Redox Biology.2018; 14: 600.     CrossRef
• Serum titers of autoantibodies against α-synuclein and tau in child- and adulthood
  Isabell Kuhn, Tobias Rogosch, Theresa I. Schindler, Björn Tackenberg, Michael Zemlin, Rolf F. Maier, Richard Dodel, Yannick Kronimus
  Journal of Neuroimmunology.2018; 315: 33.     CrossRef
• Beneficial Effects of Flavonoids Against Parkinson's Disease
  Un Ju Jung, Sang Ryong Kim
  Journal of Medicinal Food.2018; 21(5): 421.     CrossRef
• Unconventional protein secretion – new insights into the pathogenesis and therapeutic targets of human diseases
  Jiyoon Kim, Heon Yung Gee, Min Goo Lee
  Journal of Cell Science.2018;[Epub]     CrossRef
• Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy
  Martin Kallab, Marcos Herrera-Vaquero, Malin Johannesson, Fredrik Eriksson, Jessica Sigvardson, Werner Poewe, Gregor K. Wenning, Eva Nordström, Nadia Stefanova
  Frontiers in Neuroscience.2018;[Epub]     CrossRef
• Gene therapy for neurological disorders: progress and prospects
  Benjamin E. Deverman, Bernard M. Ravina, Krystof S. Bankiewicz, Steven M. Paul, Dinah W. Y. Sah
  Nature Reviews Drug Discovery.2018; 17(9): 641.     CrossRef
• Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies
  Edward Rockenstein, Gary Ostroff, Fusun Dikengil, Florentina Rus, Michael Mante, Jazmin Florio, Anthony Adame, Ivy Trinh, Changyoun Kim, Cassia Overk, Eliezer Masliah, Robert A. Rissman
  The Journal of Neuroscience.2018; 38(4): 1000.     CrossRef
• Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects
  Julianna J. Tomlinson, Bojan Shutinoski, Li Dong, Fanyi Meng, Dina Elleithy, Nathalie A. Lengacher, Angela P. Nguyen, Greg O. Cron, Qiubo Jiang, Erik D. Roberson, Robert L. Nussbaum, Nour K. Majbour, Omar M. El-Agnaf, Steffany A. Bennett, Diane C. Lagace,
  Journal of Neural Transmission.2017; 124(6): 721.     CrossRef
• Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson’s Disease
  Xiaoli Si, Jiali Pu, Baorong Zhang
  Journal of Movement Disorders.2017; 10(2): 69.     CrossRef
• Membrane Trafficking Illuminates a Path to Parkinson’s Disease
  Takafumi Hasegawa, Naoto Sugeno, Akio Kikuchi, Toru Baba, Masashi Aoki
  The Tohoku Journal of Experimental Medicine.2017; 242(1): 63.     CrossRef
• Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
  J. Teister, F. Anders, S. Beck, S. Funke, H. von Pein, V. Prokosch, N. Pfeiffer, F. Grus
  Scientific Reports.2017;[Epub]     CrossRef
• Impact of aging immune system on neurodegeneration and potential immunotherapies
  Zhanfeng Liang, Yang Zhao, Linhui Ruan, Linnan Zhu, Kunlin Jin, Qichuan Zhuge, Dong-Ming Su, Yong Zhao
  Progress in Neurobiology.2017; 157: 2.     CrossRef
• A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies
  Jess-Karan S. Dhillon, Cara Riffe, Brenda D. Moore, Yong Ran, Paramita Chakrabarty, Todd E. Golde, Benoit I. Giasson, Stephan N. Witt
  PLOS ONE.2017; 12(9): e0184731.     CrossRef
• Vaccination strategies in tauopathies and synucleinopathies
  Anne K. Braczynski, Jörg B. Schulz, Jan‐Philipp Bach
  Journal of Neurochemistry.2017; 143(5): 467.     CrossRef
• Missions of <italic>Journal of Movement Disorders</italic>
  Yun Joong Kim
  Journal of Movement Disorders.2016; 9(1): 1.     CrossRef
• How strong is the evidence that Parkinson's disease is a prion disorder?
  Patrik Brundin, Jiyan Ma, Jeffrey H. Kordower
  Current Opinion in Neurology.2016; 29(4): 459.     CrossRef